Acrivon COO buys 10,000 shares in open market

Acrivon Therapeutics, Inc. Chief Operating Officer Eric Devroe reported an open-market purchase of company stock.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Operating Officer Eric Devroe reported an open-market purchase of company stock. On 01/13/2026, he bought 10,000 shares of Acrivon common stock at a weighted average price of $1.7218 per share, executed in multiple trades within a price range of $1.719 to $1.7268. Following this purchase, he beneficially owns 75,308 shares of Acrivon common stock in direct ownership.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Devroe Eric

Role Chief Operating Officer

Bought 10,000 shs ($17K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$1.7218	$17K

Holdings After Transaction: Common Stock — 75,308 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.

FAQ

What insider transaction did ACRV’s COO Eric Devroe report?

Acrivon Therapeutics, Inc. (ACRV) Chief Operating Officer Eric Devroe reported an open-market purchase of 10,000 shares of Acrivon common stock on 01/13/2026.

At what price did the ACRV COO buy the shares?

The shares were purchased at a weighted average price of $1.7218 per share, with individual trades executed in a range from $1.719 to $1.7268.

How many ACRV shares does Eric Devroe own after this transaction?

After the reported transaction, Eric Devroe beneficially owns 75,308 shares of Acrivon Therapeutics common stock in direct ownership.

Was this ACRV insider transaction a purchase or a sale?

The Form 4 reports a purchase transaction, coded as “P,” indicating that Eric Devroe bought additional shares of Acrivon common stock.

Is the reported ACRV transaction a single trade or multiple trades?

The filing notes that the transaction was executed in multiple trades within a price range of $1.719 to $1.7268, with the reported price being the weighted average.

Does Eric Devroe hold ACRV shares directly or indirectly?

The Form 4 indicates that the 75,308 shares are held by Eric Devroe in direct ownership, with no indirect ownership nature specified.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		P		10,000	A	$1.7218(1)	75,308	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.

	/s/ Adam D. Levy, Attorney-in-Fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.